Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

Bibliography

• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Simpson L, Galanis E. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 2006;6(11):1593-607
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl 3):11-6
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9
   PubMed Web of Science ®Google Scholar
• Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48(2):347-56
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12(17):5018-22
   PubMed Web of Science ®Google Scholar
• Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271(13):7788-95
   PubMed Web of Science ®Google Scholar
• Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4(12):1317-26
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2(10):737-44
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5(3):487-91
   PubMed Web of Science ®Google Scholar
• Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3(12 Pt 1):2187-90
   PubMed Web of Science ®Google Scholar
• Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94(2):663-8
   PubMed Web of Science ®Google Scholar
• Kaur B, Tan C, Brat DJ, et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004;70(2):229-43
   PubMed Web of Science ®Google Scholar
• Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77(2):362-72
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59(4):520-9
   PubMed Web of Science ®Google Scholar
• Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15(3):339-47
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Millauer B, et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993;53(23):5822-7
   PubMed Web of Science ®Google Scholar
• Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995;55(5):1189-93
   PubMed Web of Science ®Google Scholar
• Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84(1):10-8
   PubMed Web of Science ®Google Scholar
• Fischer I, Gagner JP, Law M, et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15(4):297-310
   PubMed Web of Science ®Google Scholar
• Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol 2006;78(3):281-93
   PubMed Web of Science ®Google Scholar
• Rong Y, Durden DL, Van Meir EG, Brat DJ. ‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65(6):529-39
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-5
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xu L, Chen Y, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61(16):6020-4
   PubMed Web of Science ®Google Scholar
• Parliament MB, Allalunis-Turner MJ, Franko AJ, et al. Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer 2000;82(3):635-41
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007;13(19):5670-4
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7(2):134-53
   PubMed Web of Science ®Google Scholar
• Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88(11):2606-18
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92(12):5510-4
   PubMed Web of Science ®Google Scholar
• Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295(5556):858-61
   PubMed Web of Science ®Google Scholar
• Pore N, Liu S, Haas-Kogan DA, et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003;63(1):236-41
   PubMed Web of Science ®Google Scholar
• Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60(20):5879-86
   PubMed Web of Science ®Google Scholar
• Ma D, Nutt CL, Shanehsaz P, et al. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors. Cancer Res 2005;65(13):5523-34
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95
   PubMed Web of Science ®Google Scholar
• Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15(4):275-86
   PubMed Web of Science ®Google Scholar
• Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005;7(4):436-51
   PubMed Web of Science ®Google Scholar
• Trojan J, Cloix JF, Ardourel MY, et al. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007;145(3):795-811
   PubMed Web of Science ®Google Scholar
• Clarke K, Smith K, Gullick WJ, Harris AL. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer 2001;84(10):1322-9
   PubMed Web of Science ®Google Scholar
• Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9(4):287-300
   PubMed Web of Science ®Google Scholar
• Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344(8915):82-6
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Rizkalla LR, Soi A, et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991;51(20):5760-5
   PubMed Web of Science ®Google Scholar
• Lamszus K, Heese O, Westphal M. Angiogenesis-related growth factors in brain tumors. Cancer Treat Res 2004;117:169-90
   PubMedGoogle Scholar
• Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006;12(13):3935-41
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002;109(6):777-85
   PubMed Web of Science ®Google Scholar
• Grau SJ, Trillsch F, Herms J, et al. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 2007;82(2):141-50
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368-80
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100(12):3131-9
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-7
   PubMed Web of Science ®Google Scholar
• Rajantie I, Ilmonen M, Alminaite A, et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004;104(7):2084-6
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6(11):835-45
   PubMed Web of Science ®Google Scholar
• Santarelli JG, Udani V, Yung CY, et al. Preuss Resident Research Award: bone marrow-derived Flk-1-expressing CD34+ cells contribute to the endothelium of tumor vessels in mouse brain. Clin Neurosurg 2005;52:384-8
   PubMedGoogle Scholar
• Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev 2004;5(10):816-26
   Google Scholar
• Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol 2005;15(4):327-41
   PubMed Web of Science ®Google Scholar
• Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Expl Cell Res 2006;312(5):651-8
   PubMed Web of Science ®Google Scholar
• Wang D, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 2005;15(4):318-26
   PubMed Web of Science ®Google Scholar
• Bello L, Francolini M, Marthyn P, et al. α(v)β3 and α(v)β5 integrin expression in glioma periphery. Neurosurgery 2001;49(2):380-9; discussion 90
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of α(v)β3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11(17):6270-9
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-77
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40
   PubMedGoogle Scholar
• Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006;33(5 Suppl 10):S35-40
   Google Scholar
• Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312(5777):1171-5
   PubMed Web of Science ®Google Scholar
• Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67(15):7055-8
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59(14):3374-8
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731-6
   PubMed Web of Science ®Google Scholar
• Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95(18):10820-5
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-63
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66(16):7843-8
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82
   PubMed Web of Science ®Google Scholar
• Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67(8):3560-4
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7(10):733-6
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the Treatemtn of Relapsed Malignant Glioma. In: Bigner DD, editor. World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology; 2005; Edinburgh, Scotland: Duke University Press; 2005. p. 369
   Google Scholar
• Goli KJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. 43rd Annual Meeting of Amercian Society of Clinical Oncology; 2007; Chicago, IL: Grunberg MD, Steven; 2007. p. 75S
   Google Scholar
• Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17(5):1516-25
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol 2004;6(1):21-7
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003;97(9 Suppl):2381-6
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006;8(2):189-93
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002;56(2):183-8
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003;9(8):2940-9
   PubMed Web of Science ®Google Scholar
• MacDonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80
   PubMed Web of Science ®Google Scholar
• Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89(3):640-6
   PubMed Web of Science ®Google Scholar
• Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106(4):601-8
   PubMed Web of Science ®Google Scholar
• Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007;9(2):89-95
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588-93
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17(9):2762-71
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572-8
   PubMed Web of Science ®Google Scholar
• Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66(8):1258-60
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a Pilot Study. J Clin Oncol 2007;25(30):4714-21
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Prodos M, Wen P, et al. A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with irinotecan prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Presented at the 12th Annual Meeting of the Society for Neuro-Oncologyl; 2007; Dallas, TX; 2007
   Google Scholar
• Raiser J, Gallot L, Levy RM, et al. A phase II safety study of bevacizumab in patients with multiplie recurrent or progressive malignant gliomas. In: Yung A, editor. Twelfth Annual Meeting of the Society of Neuro-Oncology; 2007; Dallas, TX; 2007. p. 530
   Google Scholar
• Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67(2):323-6
   PubMed Web of Science ®Google Scholar
• Rich JN, Sathornsumetee S, Keir ST, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005;11(22):8145-57
   PubMed Web of Science ®Google Scholar
• Conrad C, Friedman HS, Reardon DA, et al. A Phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):1512
   Web of Science ®Google Scholar
• Reardon DA, Friedman HS, Yung WKA, et al. A Phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):1513
   Google Scholar
• Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23(18):4162-71
   PubMed Web of Science ®Google Scholar
• Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004;4(Suppl 2):S81-5
   Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8
   PubMed Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007;67(5):1526-37
   PubMed Web of Science ®Google Scholar
• Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47(6):904-11
   PubMed Web of Science ®Google Scholar
• Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47(3):393-403
   PubMed Web of Science ®Google Scholar
• Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005;46(6):945-52
   Web of Science ®Google Scholar
• Rock JP, Hearshen D, Scarpace L, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51(4):912-9; discussion 9-20
   PubMed Web of Science ®Google Scholar
• Cha S, Yang L, Johnson G, et al. Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. Am J Neuroradiol 2006;27(2):409-17
   PubMed Web of Science ®Google Scholar
• Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24(20):3293-8
   PubMed Web of Science ®Google Scholar
• Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13(12):3449-59
   PubMed Web of Science ®Google Scholar
• Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001;51(2):478-82
   PubMed Web of Science ®Google Scholar
• Essig M, Wenz F, Scholdei R, et al. Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas. Effect of contrast medium extravasation. Acta Radiol 2002;43(4):354-9
   PubMed Web of Science ®Google Scholar
• Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am J Roentgenol 2002;178(3):711-6
   PubMed Web of Science ®Google Scholar
• Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228(2):523-32
   PubMed Web of Science ®Google Scholar
• Brubaker LM, Bullitt E, Yin C, et al. Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice. Cancer Res 2005;65(18):8218-23
   PubMed Web of Science ®Google Scholar
• Bullitt E, Reardon DA, Smith JK. A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage 2007;37(Suppl 1):S116-9
   Google Scholar
• Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-9
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16(4):558-65
   PubMed Web of Science ®Google Scholar
• Duda DG, Cohen KS, di Tomaso E, et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006;24(9):1449-53
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
   PubMed Web of Science ®Google Scholar
• Huang J, Soffer SZ, Kim ES, et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004;2(1):36-42
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7(4):452-64
   PubMed Web of Science ®Google Scholar
• De Bouard S, Guillamo JS, Christov C, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-α, angiostatin, or endostatin. Human Gene Ther 2003;14(9):883-95
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61(18):6624-8
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3(4):347-61
   PubMed Web of Science ®Google Scholar
• Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003;88:169-77
   PubMedGoogle Scholar
• Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-14
   PubMed Web of Science ®Google Scholar
• Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61(20):7501-6
   PubMed Web of Science ®Google Scholar
• Farhadi MR, Capelle HH, Erber R, et al. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 2005;102(2):363-70
   PubMed Web of Science ®Google Scholar
• de Bouard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9(4):412-23
   PubMed Web of Science ®Google Scholar